The inverse association of SFRP2 (a Wnt inhibitor) with risk scores further supports Wnt pathway activation as a hallmark of aggressive gliomas (Majchrzak-Celińska et al., 2016). The gene discussed is SFRP2; the disease is central nervous system cancer.